12/2
11:00 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
12/2
08:04 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
12/1
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
07:00 am
akba
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Medium
Report
Akebia Announces Establishment of Rare Kidney Disease Pipeline
11/24
08:00 am
akba
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/14
02:40 am
akba
Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? [Yahoo! Finance]
Medium
Report
Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? [Yahoo! Finance]
11/12
06:23 am
akba
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
11/10
07:11 am
akba
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/10
07:00 am
akba
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/6
07:03 pm
akba
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs [Yahoo! Finance]
Medium
Report
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs [Yahoo! Finance]
11/6
06:30 pm
akba
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Low
Report
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
11/4
08:00 am
akba
Akebia Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Akebia Therapeutics to Present at Upcoming Investor Conferences
11/3
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/1
01:04 am
akba
Akebia Therapeutics (NASDAQ:AKBA) was upgraded by analysts at
Wall Stree
Medium
Report
Akebia Therapeutics (NASDAQ:AKBA) was upgraded by analysts at
Wall Stree
10/30
05:45 pm
akba
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients [Yahoo! Finance]
Medium
Report
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients [Yahoo! Finance]
10/30
08:09 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at HC Wainwright from $8.00 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at HC Wainwright from $8.00 to $6.00. They now have a "buy" rating on the stock.
10/30
08:00 am
akba
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
Low
Report
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
10/29
02:28 pm
akba
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
10/28
04:30 pm
akba
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
High
Report
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
10/20
08:08 am
akba
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Medium
Report
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
10/1
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/26
05:35 am
akba
Anemia Treatment Market Analysis by Disease Type, Therapy Class, Route of Administration, Countries and Competitive Landscape 2025-2033 [Yahoo! Finance]
Low
Report
Anemia Treatment Market Analysis by Disease Type, Therapy Class, Route of Administration, Countries and Competitive Landscape 2025-2033 [Yahoo! Finance]
9/13
01:06 am
akba
Akebia Therapeutics (NASDAQ:AKBA) was downgraded by analysts at
Wall Str
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) was downgraded by analysts at
Wall Str
9/6
11:17 am
akba
Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43% [Yahoo! Finance]
Medium
Report
Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43% [Yahoo! Finance]